PRX-IIE (AT3G52960), Glutaredoxin-S12 (GRX-S12; AT2G20270), and sulfiredoxin (SRX; AT1G31170) were cloned into pET28a (Novagen, Darmstadt, Germany). Forward and reverse primer were designed with NdeI and BamHI restriction sites, respectively (Table S1). The variants C121S, C146S, C121S/C146S, S82D, T108E, and T223E of PRX-IIE were generated by site-directed mutagenesis with specific primers (Table S1). The correctness of all constructs was confirmed by DNA sequencing.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.
Tips for asking effective questions
+ Description
Write a detailed description. Include all information that will help others answer your question including experimental processes, conditions, and relevant images.